title: [APPLICATION OF DIFERELIN AND ITS PERSPECTIVES].
abstract: The article presents a brief overview of luteinizing hormone-releasing hormone analogs in the treatment of prostate cancer. The authors report their experience with this drug class by an example of Diferelin. The experience with abiraterone in treatment of patients with hormonal resistance is described.
authors.forename: L M
authors.initials: LM
authors.lastname: Rapoport
authors.forename: E A
authors.initials: EA
authors.lastname: Bezrukov
authors.forename: Ju L
authors.initials: JL
authors.lastname: Demidko
authors.forename: A V
authors.initials: AV
authors.lastname: Kondrashina
mesh_terms: D000736:Androstenes / Q000008:administration & dosage / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use*; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D013739:Testosterone / Q000097:blood; D016896:Treatment Outcome; D017329:Triptorelin Pamoate / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000736:Androstenes; D018931:Antineoplastic Agents, Hormonal; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D017430:Prostate-Specific Antigen; C089740:abiraterone